Pathios Therapeutics and Sygnature Discovery have entered a strategic partnership to accelerate Pathios’ drug discovery and development programs. As part of the agreement, Pathios and Sygnature will collaborate on an integrated drug discovery program against a novel G Protein-Coupled Receptor (GPCR) target. Specifically, Sygnature is providing their industry leading expertise in GPCR bioscience and medicinal chemistry to expand Pathios’ current hit-to-lead program. Sygnature are also deployin...